BioPharm Weekly News Roundup—Week of Oct. 13, 2025

Welcome to the BioPharm International® weekly news roundup for the week of Oct. 13, 2025. In this video feature, the editors highlight each week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week. And be sure to check the links below for more in-depth coverage of each story.

Biologics, obesity R&D partnerships, and China collaborations are driving pharmaceutical M&A and selective venture capital funding in the third quarter of 2025, according to a new report by J.P. Morgan.

Biotech equipment market growth to $144 billion by 2030 fuels pharma R&D, precision medicine, and automation across drug manufacturing, according to a BCC Research report.

CGT innovation requires a three-pronged focus on optimizing cost-effective, high-quality manufacturing for autologous, in-vivo, and allogeneic therapies.

CGT represents the future of medicine, projecting 2033 market growth; however, complex manufacturing and high costs remain key challenges.

Life science CEOs prioritize AI investment, workforce upskilling, and supply chain resilience, addressing regulatory demands and rising ethical concerns, according to a KPMG survey.

Cellevate’s new nanofiber microcarriers demonstrated a significant boost to viral vaccine titers (13-fold), offering dramatically reduced manufacturing costs by up to 85% and enhancing scalability.

CGT investment has shifted to cautious optimism, but overcoming funding challenges requires strong science, operational discipline, and strategic alternative financial models.

Rentschler Biopharma’s massive buffer media station investment strengthens European biotech competitiveness while emphasizing a global focus on biologics.

Optimizing advanced therapy manufacturing requires adoption of proven, mainstream methods and tailoring supply chain and distribution strategies for success.

Biopharma needs hands-on training, talent hubs, and long-term strategic investment to bridge the technology workforce gap for commercialization.